Pre-myeloid Cancer and Bone Marrow Failure Clinic Study

  • STATUS
    Recruiting
  • End date
    Jan 19, 2023
  • participants needed
    100
  • sponsor
    Mayo Clinic
Updated on 19 March 2021

Summary

The use of genomics and functional translational studies is to identify and diagnose patients with precursor features of myeloid neoplasms and inherited bone marrow failure syndromes.

Description

The pre-myeloid cancer and bone marrow failure clinic is an individualized medicine clinic conceptualized for the early detection of myeloid malignancies such as, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), MDS/MPN overlap syndromes and acute myeloid leukemia (AML). Using next-generation sequencing technologies, clonal hematopoietic stem cell changes can be detected early on in myeloid malignancies. These changes are currently classified as follows:

  1. Idiopathic cytopenias of unclear significance (ICUS).
  2. Clonal cytopenias of unclear significance (CCUS).
  3. Clonal hematopoiesis of indeterminate prognosis (CHIP).
  4. Bone marrow failure syndromes with risk for clonal myeloid transformation.
  5. Familial/Germline syndromes with increased risk for myeloid malignancies.

This clinic blends next-generation sequencing technologies with functional studies to help identify, prognosticate and define management plans; including early intervention strategies, for affected patients.

Details
Condition Cytopenia, Myeloid Neoplasm, Myeloid Malignancy, Inherited Bone Marrow Failure Syndrome, Clonal Expansion, cytopenias
Treatment Follow Up
Clinical Study IdentifierNCT02958462
SponsorMayo Clinic
Last Modified on19 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patients with
Idiopathic cytopenias of unclear significance (ICUS)
Clonal hematopoiesis of indeterminate significance (CHIP)
Age related clonal hematopoiesis (ARCH)
Clonal cytopenias of unclear significance (CCUS)
Marrow failure syndromes with myeloid malignancy predisposition- telomere dysfunction, chromosomal breakage disorders, etc
Germ line inherited syndromes with risk for malignant transformation
Low Risk Myelodysplastic Syndromes (MDS)

Exclusion Criteria

Patients who are unable to understand and sign the Informed Consent Form
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note